Related references
Note: Only part of the references are listed.
Article
Oncology
Andreas Volk et al.
Summary: Patients with immune deficiencies often receive antibodies from healthy donors as a first line of defense against infections. Research shows that plasma-derived immunoglobulin lots produced between December 2020 and June 2021 have increasing neutralizing activity against SARS-CoV-2 over time.
Article
Allergy
Michele N. Pham et al.
Summary: The study assessed the immune responses in patients with PID after receiving COVID-19 mRNA vaccines. It was found that cellular immunity was stimulated in most patients, but antibody responses to the spike protein RBD were inconsistent and ineffective at ACE2 blocking in some cases.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2022)
Article
Immunology
Daniel Arroyo-Sanchez et al.
Summary: Common Variable Immunodeficiency (CVID) patients show slower humoral and cellular responses to COVID-19 vaccination compared to healthy controls. Despite most CVID patients developing S1-specific antibodies and T cells after vaccination, neutralizing antibodies were only detected in half of the patients. Those with absent or discordant responses often had a history of autoimmunity or lymphoproliferation, while recent anti-B cell antibody therapy may also weaken the response. Further studies are necessary to assess the protective efficacy of COVID-19 vaccination in CVID patients, with consideration for a third dose to achieve full immune response.
JOURNAL OF CLINICAL IMMUNOLOGY
(2022)
Article
Microbiology
Kahina Saker et al.
Summary: This study compared the antibody titers obtained with different commercial binding antibody assays after one or two doses of vaccine in healthcare workers. The results showed 100% seroconversion with all evaluated assays after two doses of vaccine. The antibody titers were correlated between assays allowing correction, but significant differences still persisted. Standardization of the assays should include the International Standard for uniform expression of results.
JOURNAL OF CLINICAL MICROBIOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Samuel M. S. Cheng et al.
Summary: Specific antibody levels against the SARS-CoV-2 Omicron variant decrease significantly after two doses of BNT162b2 or CoronaVac vaccines, but can be markedly increased with a booster dose of BNT162b2. Individuals who previously received two doses of BNT162b2 or CoronaVac showed reduced serum antibody titers against Omicron, while a BNT162b2 booster dose increased the antibody levels in the majority of individuals. This suggests mRNA vaccine boosters may be necessary in countries primarily using CoronaVac vaccines to combat the spread of Omicron.
Article
Virology
Syed Faraz Ahmed et al.
Summary: The study assessed the impact of Omicron mutations on known T cell epitopes and found that T cell responses to this new variant remain robust.
Article
Immunology
Isabella Quinti et al.
Summary: This article examines the effects of vaccination on CVID patients and the immune response post SARS-CoV-2 infection. It found that different types of memory B cells are generated after vaccination, and the immune response varies among individuals.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Cell Biology
Yihao Liu et al.
Summary: SARS-CoV-2 inactivated vaccines have demonstrated significant efficacy in reducing severe illness and death. Despite a decline in humoral immunity over time, memory B and T cells remain detectable and can provide a quick recall response. A third booster dose enhances the immune response and improves the durability of protective immunity. Additionally, healthcare workers with low serological response to two doses still possess immune memory that can be quickly recalled by a third dose.
Article
Allergy
Sudhir Gupta et al.
Summary: The study examined subsets of CD4+ and CD8+ T cells, B cells, and regulatory lymphocytes in an immunocompetent patient and a CVID patient, revealing different patterns of abnormalities. The immunocompetent patient showed greater changes in various subsets compared to the CVID patient, indicating different immunological responses to SARS-CoV-2 infection.
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY
(2021)
Article
Immunology
Ane Fernandez Salinas et al.
Summary: After BNT162b2 vaccination, some patients with primary antibody deficiencies exhibited atypical immune responses, possibly due to extra-follicular reactions or incomplete germinal center reactions. It remains unknown whether these responses to the vaccine might provide partial protection from infection or reinfection.
JOURNAL OF CLINICAL IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Shuo Feng et al.
Summary: Defined levels of SARS-CoV-2-specific binding and neutralizing antibodies elicited by the COVID-19 vaccine were identified as correlates of protection against symptomatic infection. Higher levels of immune markers were correlated with a reduced risk of symptomatic infection. The data can be used to extrapolate efficacy estimates to new populations.
Article
Immunology
Jacqueline Squire et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
(2021)
Article
Medicine, General & Internal
Peter Bergman et al.
Summary: This prospective clinical trial investigated the safety and efficacy of the BNT162b2 mRNA vaccine in immunocompromised patients and healthy controls. The vaccine was found to be safe in immunocompromised patients, but with a lower seroconversion rate compared to healthy controls. Additional vaccine doses may be needed to improve immunity in certain immunocompromised patient groups.
Article
Immunology
Maria R. Farcet et al.
Summary: The study found that the levels of SARS-CoV-2 neutralizing antibodies in immunoglobulin lots released since March 2020 have been steadily increasing, reaching a high level by January 2021. It is projected that by July 2021, the anti-SARS-CoV-2 potency in immunoglobulins could further enhance.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Letter
Medicine, General & Internal
Paul A. Kristiansen et al.
Article
Allergy
David Hagin et al.
Summary: The study evaluated the humoral and cellular immune response to the COVID-19 vaccine in patients with IEI, finding that most patients were able to develop vaccine-specific antibody response and S-protein-specific cellular response, and no significant adverse events were reported during the vaccination process.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2021)
Article
Immunology
L. Westh et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY
(2017)
Review
Immunology
R. Ameratunga et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
(2013)
